Two Sigma was co-founded in 2001 by John Overdeck and David Siegel in NYC. The technology-driven investment team streamlines the use of machine learning, distributed computing and research to guide its endeavors.  It develops systematic tools using engineering and data science to make investment decisions.  Some of its clients include: government agencies, educational institutes, non-profits and pension funds.

Two Sigma

Digitalis is a venture capital firm that that invests in solutions to complex problems in human and animal health.  Digitalis partners with entrepreneurs, inventors, and scientists across all stages of venture investing, and our investments span the full continuum of the healthcare ecosystem. It was founded in 2016 and is Headquartered in New York, New York with regional offices in Boston, Los Angeles, and San Francisco.

Digitalis Ventures

KdT Ventures is an early-stage venture capital firm that invests in startups in the data, engineering, and biology sector, as well as healthcare technology systems, pharmaceuticals, biotechnology, agriculture, chemicals, gases, and life sciences. The firm was founded in 2017 in Austin, Texas by Cain McClary.

KdT Ventures

Two Sigma Ventures is an early-stage venture capital fund based in New York City investing capital and expertise in entrepreneurs leveraging data and computing to create the future. In partnership with our parent company, Two Sigma Investments, we provide entrepreneurs access to a proprietary network of experts and startup resources to give them a competitive edge.

Two Sigma Ventures

Madrona Venture Group is a Seattle-based venture capital firm. The firm prefers to invest in businesses that are involved in information technology, e-commerce, digital media, advertising, software, gaming, data, analytics, mobile, and infrastructure.

Madrona

Goldcrest is a venture capital fund that invests in private technology companies. The firm was founded in 2016 and is headquartered in Dallas, Texas, USA.

Goldcrest Capital

Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that are developing transformative new modalities and platforms to meaningfully improve human health.

Alexandria Venture Investments

Sahsen Ventures is a venture capital firm making investments in for-profit and nonprofit organizations with an emphasis on technology and biotechnology. It was established in 2016 and is based in Seattle, Washington.

Sahsen Ventures

XTX Ventures is the venture capital arm of XTX Markets. XTX Markets is a leading, innovation-driven algorithmic trading firm. XTX Ventures focuses on early stage startups (Seed to Series A) applying machine learning and leverages XTX Markets’ deep expertise in ML and financial technology to help grow and enhance those businesses. We are geography and industry agnostic.

XTX Ventures

Greentrail Capital is an investment company that focuses on publicly traded and private growth-stage technology companies. The company was founded in 2020 and is headquartered in London, United Kingdom.

Greentrail Capital

Bienville is an investment advisory and asset management business managing capital on behalf of family offices and top performing institutional investors. We invest across public and private markets, crypto and venture capital, and through our partnership with Fractal we launch around 25 SaaS companies per year.

Bienville Capital

Bedford Ridge Capital is a private equity firm that focuses on financial advisory services. The firm was founded in 2020 and is based in New York.

Bedford Ridge Capital

NVentures is a venture capital firm that invests in early-stage technology companies, focusing on innovations in various sectors. NVentures is the venture capital arm of NVIDIA.

NVentures

Maverick Capital is a registered investment advisor managing private investment funds exclusively for qualified investors. They are committed to preserving and growing investors' capital.  Maverick Capital is a long/short equity hedge fund in Dallas, TX.

Maverick Capital

What If Ventures invests in stigmatized verticals within the healthcare market. For too long, stigma has artificially suppressed demand for care in indications such as mental health, fertility, and many others.  Societal changes are creating markets where stigma once stood in the way of people getting the care they need. The firm was founded in 2019 by Stephen Hays, after his own personal struggles with mental health and addiction fueled his desire to see more funding for solutions in that space.  Since then, the firm has broadened its aperture and has deployed nearly $80mm into more than 60 disruptive healthcare startups.

What If Ventures

Terray Therapeutics

Terray Therapeutics is a biotechnology company that integrates experimentation and computation to enhance small molecule drug discovery. The platform generates extensive, precise data through a rapid design-make-test-analyze cycle, allowing for efficient exploration of chemical space. By focusing on both wet lab science and AI, the company addresses complex therapeutic challenges across various targets.

<div>Terray Therapeutics focuses on the discovery and development of small-molecule drugs using its proprietary computational platform TNova. It leverages AI to synthesize, screen, and analyze chemical compounds as well as map biochemical interactions with diseases to identify the highest potential molecules for drug development. The platform&rsquo;s dataset includes more than 2 billion unique target-ligand binding measurements, which increases by 150 million each month.</div>

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

Terray Therapeutics Closes $120M Series B Funding Round

Bristol-Myers Squibb

Terray Therapeutics partners with Bristol Myers Squibb to discover and develop small molecule therapeutics using its tNova platform.

Calico

Under the terms of the agreement, the parties would identify small molecule leads against a set of targets nominated by Calico leveraging on the Terray tNova platform, with Calico eventually taking up responsibility for development and commercialization. Terray would get an upfront payment and receive milestones, along with tiered royalties on net sales

Longevity Tech

Companies involved in the development of novel small molecules or chemical drugs that target specific proteins or pathways in the body to treat age-related diseases as well as the identification of existing drugs that can be repurposed for the treatment of such diseases

<div>
 
 Terray Therapeutics focuses on the discovery and development of small-molecule drugs using its proprietary computational platform TNova. It leverages AI to synthesize, screen, and analyze chemical compounds as well as map biochemical interactions with diseases to identify the highest potential molecules for drug development. The platform&rsquo;s dataset includes more than 2 billion unique target-ligand binding measurements, which increases by 150 million each month.
 
 
 The platform uses a closed-loop system, which enables it to reassess potential candidates based on their performances. Terray&rsquo;s platform can be applied to any disease area; however, as of 2024, the company had been focusing on immunology diseases.
 
 
 Key customers and partnerships
 
 
 The company has several key partners for drug discovery, including 1) Bristol Myers Squibb to pursue the discovery and development of novel small-molecule therapeutics (
 <a href="https://sp-edge.com/updates/24922">
 December 2023
 </a>
 ) and 2) Calico Life Sciences (Google&rsquo;s anti-aging healthcare company) to develop novel small-molecule therapeutics for age-related diseases, including cancer (
 <a href="https://sp-edge.com/updates/13768">
 October 2022
 </a>
 ).
 
 
 Funding and financials
 
 
 In 
 <a href="https://sp-edge.com/updates/23753">
 November 2023
 </a>
 , the company received an undisclosed amount of equity investment from NVIDIA's venture arm, NVentures, for small-molecule drug discovery. New and existing institutional investors, including John Maraganore, the founding CEO of Alnylam Pharmaceuticals, and Bassil Dahiyat, the founder and CEO of Xencor, also contributed to the round. Before this, the company had raised USD 60 million in a Series A funding round led by Madrona Venture Group when it emerged from stealth in 
 <a href="https://sp-edge.com/updates/8508">
 February 2022
 </a>
 . 
 
</div>

<div>
 
 HiberCell is a biotechnology company that develops novel therapies focused on oncology. It entered the AI drug discovery space when it acquired AI genomics analysis company Genuity Science (and its subsidiaries in Iceland and Ireland) in August 2021.&nbsp;
 
 
 Genuity Science&rsquo;s solutions include end-to-end therapeutic discovery and development services such as building custom disease datasets, discovering and prioritizing targets, identifying biomarkers, and optimizing clinical trials. Genuity Science leverages its AI-powered platform to manage, process, and analyze genomic data. HiberCell intends to use Genuity Science&rsquo;s AI/ML capabilities to advance its oncology pipeline of five programs, of which one has reached the Phase 2 clinical trial stage.
 
 
 As of March 2024, the company&rsquo;s pipeline included three drug candidates, namely: 1) HC-7366, targeting the general control nonderepressible 2 (GCN2) kinase as part of the integrated stress response (ISR) signaling pathway; 2) HC-5404, aimed at inhibiting the PKR-like endoplasmic reticulum kinase (PERK) involved in the unfolded protein response (UPR) signaling pathway; and 3) odetiglucan, a therapy targeting tumor-immune interactions within the tumor microenvironment​.&nbsp;
 
 
 Key customers and partnerships
 
 
 In December 2023, HiberCell and Merck &amp; Co partnered to conduct a Phase Ib trial to evaluate the combination therapy of belzutifan and HC-7366 for treating clear cell renal cell carcinoma. Further, in January 2021, the company partnered with Biodesix to develop an enzyme-linked immunosorbent assay as a companion diagnostic test.
 
 
 Funding and financials
 
 
 In 
 <a href="https://hibercell.com/news/hibercell-closes-67-4-million-series-b-financing-and-secures-30-million-debt-facility-from-hercules-capital/">
 May 2021
 </a>
 , HiberCell completed a Series B financing round, raising USD 67.4 million, and secured an additional USD 30 million in debt financing from Hercules Capital. The funds were expected to be used for clinical advancement of its novel therapeutic candidates. 
 
</div>

HiberCell

<div>
 
 Arbor Biotechnologies specializes in gene editing to develop novel therapeutics for a variety of indications, starting with liver-related diseases. It operates an AI-powered biodiscovery platform to discover novel CRISPR enzymes, which are sequences of repeating genetic code. To do this, its platform deploys computational search techniques, genome sequencing, gene synthesis, and high-throughput screening. This can eventually be turned into drugs or even applied to agriculture and other industrial uses. In 2018, the company announced the discovery of Cas13d, a new type of gene editing enzyme that helps to alter RNA to treat genetic diseases.&nbsp;
 
 
 As of February 2024, the company had five internal drug discovery programs, of which one was in the IND-enabling stage. It also has multiple collaborative programs under development focused on oncology and various other therapeutic areas.
 
 
 Key customers and partnerships
 
 
 The company has a long-standing partnership with Vertex Pharmaceuticals since
 <a href="https://www.businesswire.com/news/home/20190103005194/en/Vertex-and-Arbor-Biotechnologies-Establish-Collaboration-to-Discover-Novel-Proteins-to-Advance-Discovery-of-Gene-Editing-Therapies">
 January 2019
 </a>
 , which focused on developing gene-editing treatments for cystic fibrosis and four other diseases. The alliance was further extended in 
 <a href="https://www.biospace.com/article/vertex-and-arbor-strike-a-1-2-billion-deal-for-gene-editing-programs/">
 August 2021
 </a>
 and 
 <a href="https://sp-edge.com/updates/15741">
 January 2023
 </a>
 .&nbsp;
 
 
 Other partnerships included a collaboration with 
 <a href="https://www.prnewswire.com/news-releases/arbor-biotechnologies-announces-collaboration-with-ginkgo-bioworks-to-advance-the-discovery-and-development-of-precision-gene-editors-302011991.html">
 Ginkgo Bioworks
 </a>
 (December 2023) to leverage Ginkgo's R&amp;D services to further optimize Arbor's novel precision editors, a non-exclusive licensing agreement with 
 <a href="https://www.globenewswire.com/news-release/2022/02/08/2380680/0/en/EdiGene-and-Arbor-Biotechnologies-Announce-Worldwide-Non-exclusive-License-Agreement-to-Advance-Ex-Vivo-Engineered-Cell-Therapy-Programs.html">
 EdiGene
 </a>
 (February 2022) to leverage Arbor&rsquo;s platform for ex vivo oncology therapies, a strategic research and non-exclusive licensing agreement with 
 <a href="https://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-and-arbor-biotechnologies-establish">
 TCR2 Therapeutics
 </a>
 (January 2022) to develop allogeneic TRuC T-cell therapies using Arbor&rsquo;s CRISPR technology, and a license agreement with 
 <a href="https://www.lonza.com/news/2020-12-23-14-00">
 Lonza
 </a>
 (December 2020) to use Arbor&rsquo;s gene-editing technology for Lonza&rsquo;s bioproduction products and services.
 
 
 Funding and financials
 
 
 In its latest Series B funding round in November 2021, which was led by Ally Bridge Group, TCG Crossover, and Temasek, Arbor Biotechnologies raised USD 215 million. The proceeds of the round were earmarked to fuel the company&rsquo;s clinical development pipeline.
 
</div>

Arbor Biotechnologies

Based in the UK, Arctoris provides an automated drug discovery platform, offering fully validated research and development (R&amp;D) processes under an Experiments-as-a-Service model. The company works with biotechnology companies, AI drug discovery companies, pharma and academic institutions enabling these institutions to run experiments in Arctoris’s platform and provides on-demand access to a broad scale of datasets for AI drug discovery companies to train their algorithms.

Arctoris

<div>
 
 Frontier Medicines leverages AI/ML technologies to develop treatments for cancer-causing proteins that are dismissed by traditional pharma companies as undruggable.&nbsp;
 
 
 The company has a proprietary chemoproteomic platform which entails an approach based on the interaction of small-molecule compounds and proteins to screen a large number of targets and combine them with a protein database that contains more than 150,000 novel binding pockets (hotspots). This enables it to access 90% of the human proteome that were not previously targeted due to lack of hotspots. The platform&rsquo;s AI/ML engine incorporates a library of diverse compounds, a hotspot map that serves as the starting point for understanding the druggability of a potential therapeutic target, and lead design and generation.&nbsp;
 
 
 The company focuses on oncology and immunology target and, as of February 2024, it had five wholly-owned therapeutic programs and three AbbVie-partnered programs in its pipeline. All programs were in their discovery stage, except the company&rsquo;s lead candidate, FMC-376 (activated and inactivated forms), focused on treating different cancer types, including non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC), and pancreatic ductal adenocarcinoma (PDAC), which is in the IND-enabling stage.
 
 
 Key customers and partnerships
 
 
 The company entered a USD 100 million partnership with 
 <a href="https://news.abbvie.com/2020-12-02-AbbVie-and-Frontier-Medicines-Establish-Global-Partnership-to-Discover-and-Develop-Novel-Therapies-and-E3-Degraders-Against-Difficult-to-Drug-Targets">
 AbbVie
 </a>
 In December 2020 to develop small-molecule therapeutics against hard-to-drug protein targets including around 600 E3 ligases (the enzymes that drive the ubiquitination and degradation of proteins.&nbsp;
 
 
 Funding and financials
 
 
 In July 2021, the company raised USD 88.5 million in a 
 <a href="https://sp-edge.com/updates/4347">
 Series B
 </a>
 funding round co-led by Woodline Partners LP and RA Capital Management, with equal participation from Deerfield Management Company. The proceeds were earmarked for advancing the company&rsquo;s drug pipeline and expanding operations in Boston, where its new facility was to complement the company&rsquo;s headquarters in California. 
 
</div>

Frontier Medicines

<div>
 
 Verge Genomics is a biotechnology company engaged in developing therapeutics for neurological diseases using human genomics and AI to accelerate drug discovery. The main target areas are Amyotrophic Lateral Sclerosis (ALS), Parkinson&rsquo;s Disease (PD), and Frontotemporal Dementia (FTD).&nbsp;
 
 
 It has built a proprietary all-human platform (unlike standard clinical trials that rely on animal data), called CONVERGE, that uses data sets from brain tissue samples of deceased patients with ALS and PD. While most drugs target only one gene at a time, the company claims its technology can identify hundreds of genes that cause disease and develop drugs that target all the genes at the same time. The company uses AI technology to optimize the drug discovery process as a whole.
 
 
 As of March 2024, Verge had one drug candidate in the clinical stage (Phase I) and 10 drug candidates in the discovery stage.&nbsp;
 
 
 Key customers and partnerships
 
 
 The company has partnerships with various tissue banks (such as Harvard University and University of Miami Miller School of Medicine) and several educational institutes and foundations (such as Target ALS, Answer ALS) that enabled its drug discovery platform.&nbsp;
 
 
 In addition, the company&rsquo;s customers include several pharmaceutical companies, such as 1) 
 <a href="https://www.vergegenomics.com/news-blog/verge-genomics-announces-research-collaboration-with-the-sheffield-institute-for-translational-neuroscience">
 Sheffield Institute for Translational Neuroscience (SITraN)
 </a>
 to accelerate the validation of novel drug targets and screening of drug compounds for Parkinson's disease (February 2021), 2) 
 <a href="https://sp-edge.com/updates/4146">
 Eli Lilly
 </a>
 to research and develop novel therapies to treat ALS (July 2021), 3) 
 <a href="https://sp-edge.com/updates/21707">
 Alexion
 </a>
 to identify novel drug targets for rare neurodegenerative and neuromuscular diseases (September 2023), and 4) 
 <a href="https://www.vergegenomics.com/news-blog/verge-genomics-and-the-pritzker-neuropsychiatric-disorders-research-consortium-form-cutting-edge-schizophrenia-research-collaboration">
 Pritzker Neuropsychiatric Disorders Research Consortium
 </a>
 to analyze data from schizophrenic patient&rsquo;s brain tissue with Verge&rsquo;s technology (October 2023).
 
 
 Funding and financials
 
 
 In December 2021, Verge raised USD 98 million in an oversubscribed 
 <a href="https://sp-edge.com/updates/7426">
 Series A
 </a>
 funding round led by BlackRock. The funds were used to scale up its pre-clinical and clinical candidate programs in the pipeline and enhance its lead therapeutics through clinical testing. 
 
</div>

Verge Genomics

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies for drug discovery services such as target selection, validation and lead optimization.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to design and run preclinical experiments.

SaaS (Software-as-a-Service) companies providing their ML platform to other pharma companies to identify biomarkers (measurable biological signs used to determine disease progression) and predict drug response. 

SaaS (Software-as-a-Service) companies aggregating and analyzing biomedical data with the help of AI to generate insights across the drug development pipeline.

Biotechnology companies that have integrated AI as a core component of their in-house drug development process. They typically have a few in-house drug development programs, and also collaborate with pharma companies to develop certain drugs.

Companies leverage GenAI to support drug discovery through accelerated drug designing

Companies offer AI/ML-based SaaS products to accelerate the discovery and development of novel therapeutics

Offers AI/ML-based solutions to accelerate drug discovery and development

<div> 

AI biotech firm, Terray Therapeutics, based in California, successfully raised a substantial amount of USD 120 million in a Series B funding round. The round saw significant financial injections from Bedford Ridge Capital and NVentures, among investors like Madrona Ventures and Maverick Capital.
Terray Therapeutics plans to utilize this funding to push internal programs towards clinical trials and simultaneously work on enhancing its integrated AI platform, tNova.

</div>

Terray Therapeutics

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless